We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study.
- Authors
Harashima, Shin‐ichi; Inagaki, Nobuya; Kondo, Kazuoki; Maruyama, Nobuko; Otsuka, Makiko; Kawaguchi, Yutaka; Watanabe, Yumi
- Abstract
Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are antihyperglycaemic agents with weight‐lowering effects. The efficacy and safety of the SGLT2 inhibitor canagliflozin as add‐on therapy in Japanese patients with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control with a GLP‐1RA (≥12 weeks) were evaluated in this phase IV study. Patients received canagliflozin 100 mg once daily for 52 weeks. Efficacy endpoints included change in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP) and HDL cholesterol from baseline to week 52. Safety endpoints included adverse events (AEs), hypoglycaemia and laboratory tests. Of the 71 patients treated with canagliflozin, 63 completed the study. At 52 weeks, HbA1c was significantly reduced from baseline (−0.70%; paired t test, P < .001). Significant changes were also observed in FPG (−34.7 mg/dL), body weight (−4.46%), SBP (−7.90 mm Hg), and HDL cholesterol (7.60%; all P < .001). The incidence of AEs, adverse drug reactions and hypoglycaemia was 71.8%, 32.4% and 9.9%, respectively. All hypoglycaemic events were mild. These findings suggest that the long‐term combination of canagliflozin with a GLP‐1RA is effective and well tolerated in Japanese patients with T2DM.
- Subjects
CANAGLIFLOZIN; TYPE 2 diabetes diagnosis; GLYCEMIC index; SYSTOLIC blood pressure; DRUG side effects; PREVENTION; THERAPEUTICS
- Publication
Diabetes, Obesity & Metabolism, 2018, Vol 20, Issue 7, p1770
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.13267